Teva is not alone here; Tysabri's price was hiked by 7% on Dec. and by 19% in June 2010. Looks like Gilenya's annual price at $48K gave a push to other MS drugs' pricing .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.